These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
476 related articles for article (PubMed ID: 38518167)
1. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer. Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167 [TBL] [Abstract][Full Text] [Related]
2. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures. Dong Y; Wu X; Xu C; Hameed Y; Abdel-Maksoud MA; Almanaa TN; Kotob MH; Al-Qahtani WH; Mahmoud AM; Cho WC; Li C Aging (Albany NY); 2024 Feb; 16(3):2591-2616. PubMed ID: 38305808 [TBL] [Abstract][Full Text] [Related]
3. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer. Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764 [TBL] [Abstract][Full Text] [Related]
4. Construction and validation of a prognostic model for bladder cancer based on disulfidptosis-related lncRNAs. Yang X; Zhang Y; Liu J; Feng Y Medicine (Baltimore); 2024 Jul; 103(27):e38750. PubMed ID: 38968515 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B Front Immunol; 2022; 13():931906. PubMed ID: 35958598 [TBL] [Abstract][Full Text] [Related]
6. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma. Chen L; Lin J; Wen Y; Chen Y; Chen CB Front Oncol; 2023; 13():1291720. PubMed ID: 38023241 [TBL] [Abstract][Full Text] [Related]
7. Advancing bladder cancer management: development of a prognostic model and personalized therapy. Huang X; Du G; Yang Y; Su P; Chen S; Cai C; Huang T; Zeng Y; Tao Y; Tian D; Zhang N Front Immunol; 2024; 15():1430792. PubMed ID: 39104534 [TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer. Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H Front Immunol; 2023; 14():1213947. PubMed ID: 37965307 [TBL] [Abstract][Full Text] [Related]
9. Construction and validation of a bladder cancer risk model based on autophagy-related genes. Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018 [TBL] [Abstract][Full Text] [Related]
10. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis. Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402 [TBL] [Abstract][Full Text] [Related]
11. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer. Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230 [TBL] [Abstract][Full Text] [Related]
12. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and immunotherapy response in bladder cancer. Shi X; Dong A; Yang Y; Zheng G; Wang N; Yang C; Wang Y; Lu J; Jia X J Cancer Res Clin Oncol; 2023 Sep; 149(12):9733-9746. PubMed ID: 37244876 [TBL] [Abstract][Full Text] [Related]
13. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer. Tan Z; Fu S; Zuo J; Wang J; Wang H Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832 [TBL] [Abstract][Full Text] [Related]
14. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer. Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720 [TBL] [Abstract][Full Text] [Related]
15. Developing and experimental validating a B cell exhaustion-related gene signature to assess prognosis and immunotherapeutic response in bladder cancer. Zhou R; Zhou J; Deng S; Zhu Y; Muhuitijiang B; Wu J; Tan W Gene; 2024 Nov; 927():148634. PubMed ID: 38848880 [TBL] [Abstract][Full Text] [Related]
16. Discovery of a T cell proliferation-associated regulator signature correlates with prognosis risk and immunotherapy response in bladder cancer. Yan T; Zhou W; Li C Int Urol Nephrol; 2024 Nov; 56(11):3447-3462. PubMed ID: 38789872 [TBL] [Abstract][Full Text] [Related]
17. Identification of a Prognosis-Related Risk Signature for Bladder Cancer to Predict Survival and Immune Landscapes. Wang L; Wang Y; Wang J; Li L; Bi J J Immunol Res; 2021; 2021():3236384. PubMed ID: 34708131 [TBL] [Abstract][Full Text] [Related]
18. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer. Wang Z; Tu L; Chen M; Tong S BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144 [TBL] [Abstract][Full Text] [Related]
19. Development of prognostic model incorporating a ferroptosis/cuproptosis-related signature and mutational landscape analysis in muscle-invasive bladder cancer. Hao S; Yang Z; Wang G; Cai G; Qin Y BMC Cancer; 2024 Aug; 24(1):958. PubMed ID: 39107713 [TBL] [Abstract][Full Text] [Related]
20. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer. Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P Front Oncol; 2023; 13():972558. PubMed ID: 37064115 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]